Kyselina Ibandrónová Sandoz (Sodium Ibandronate)

Ibandronate sodium belongs to the bisphosphonate class and is indicated for conditions involving excessive bone resorption.

• Osteoporosis: reduces the risk of vertebral and non‑vertebral fractures in post‑menopausal women and men with primary osteoporosis.
• Paget's disease of bone: normalises bone turnover and alleviates bone pain associated with the disorder.

• Ibandronate sodium binds avidly to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the ibandronate‑coated bone surface, the drug is internalised, inhibiting farnesyl pyrophosphate synthase within the mevalonate pathway. This disruption triggers osteoclast apoptosis, thereby decreasing bone resorption and stabilising bone mass.

Ibandronate sodium may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia.
• Constipation or diarrhoea.
• Musculoskeletal pain or arthralgia.
• Transient flu‑like symptoms.

Serious or Rare Side Effects

• Osteonecrosis of the jaw, especially after invasive dental procedures.
• Atypical femoral fractures.
• Severe hypersensitivity reactions, including rash or anaphylaxis.
• Acute renal impairment or worsening of pre‑existing kidney disease.
• Severe oesophagitis or oesophageal ulceration.

Before initiating ibandronate therapy, clinicians should consider several safety measures.

• Renal function: assess baseline creatinine clearance and avoid use in severe renal impairment.
• Calcium/Vitamin D status: ensure adequate supplementation to support bone health.
• Gastrointestinal administration: take with a full glass of water and remain upright for at least 30 minutes to reduce oesophageal irritation.
• Concomitant medications: avoid simultaneous use of other bisphosphonates or drugs that may impair renal function.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ibandronate can interact with several medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Other bisphosphonates: concurrent use increases risk of oversuppression of bone turnover.
• Antacids or supplements containing calcium, magnesium, aluminium or iron: they bind ibandronate and markedly reduce absorption.
• Nephrotoxic agents (e.g., aminoglycosides, cisplatin): may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely)

• Oral corticosteroids: may increase risk of gastrointestinal irritation.
• Proton pump inhibitors: can affect gastric pH and potentially alter ibandronate absorption.
• Thiazide diuretics: may influence calcium balance and renal handling.
• Vitamin D analogues: monitor calcium levels to avoid hypercalcaemia.